This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Bayer/Evotec Kidney Program
Drug Names(s): Bayer/Evotec Kidney Program
Description: Evotec and Bayer are developing clinical candidates for the treatment of kidney diseases.
Bayer and Evotec
In September 2016, Evotec announced that Evotec and Bayer have entered into a five-year, multi-target research partnership. The goal is the development of multiple clinical candidates for the treatment of kidney diseases such as chronic kidney disease in diabetes patients. Both companies will contribute novel drug targets and a comprehensive set of high-quality technology platforms to jointly develop innovative treatment options for these severe conditions. The partners will share responsibilities during pre-clinical development of potential clinical candidates.
Under the terms of the agreement, Bayer will receive exclusive access to selected candidates as well as to Evotecs CureNephron target pipeline. Bayer will be responsible for any subsequent clinical development and commercialisation. Evotec will receive a minimum of 14 m over the contract period including research payments and an undisclosed licence fee. In addition, Evotec is eligible to...See full deal structure in Biomedtracker
Partners: Evotec AG
Bayer/Evotec Kidney Program News
Additional information available to subscribers only: